Contemporary uses of erythropoietin in pregnancy

A literature review

Laura Sienas, Tienne Wong, Rebecca Collins, James Smith, Jr.

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

OBJECTIVE: The objectives of this study were to survey the current research and provide an update on the uses and benefits of erythropoietin (EPO) in pregnancy and the postpartum period. DATA SOURCES: A review of MEDLINE (1947 to present) was performed. Search terms included "erythropoietin," "pregnan*," with subheadings of "administration & dosage," "pharmacokinetics," "therapeutic use," "fetus," "fertility." METHOD OF STUDY SELECTION: We reviewed relevant articles published from 2002 to 2012. Case reports, observational studies, case-control studies, randomized controlled trials, retrospective analyses, animal studies, and review articles were included. Articles were selected if they discussed a use of EPO in pregnancy or the immediate postpartum period, as well as use of EPO in the neonate. TABULATION, INTEGRATION, AND RESULTS: Authors independently reviewed and extracted data. Of the 65 articles reviewed, 45 were included. Erythropoietin was used in the treatment of maternal anemia. Because of the molecule's large size, recombinant EPO does not appear to cross the placenta. No fetal morbidity or mortality was noted. Therefore, this is a safe therapy that can be used in pregnancy. Use of EPO may be especially important for women who decline blood products. Neonatal uses of EPO show benefit in the treatment of anemia due to blood type incompatibility. CONCLUSIONS: Erythropoietin is gaining popularity as a therapeutic option during pregnancy and the postpartum period. Further investigation is needed to establish a standard dosage and dosing interval. New studies reviewing its use in the neonate for perinatal-hypoxic injury and anemia due to blood type incompatibility provide exciting opportunities for further therapeutic use. TARGET AUDIENCE: Obstetricians and gynecologists, family physicians LEARNING OBJECTIVES: After completing this CME activity, physicians should be better able to treat anemia in pregnancy, including causes and interventions; assess renal disease in pregnancy, targets of hemoglobin, precautions, and treatment considerations; and evaluate erythropoietin use in neonates and fetuses, including benefits, complications, and areas for upcoming research/uses.

Original languageEnglish
Pages (from-to)594-602
Number of pages9
JournalObstetrical and Gynecological Survey
Volume68
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

Erythropoietin
Pregnancy
Anemia
Postpartum Period
Newborn Infant
Therapeutic Uses
Fetus
Therapeutics
Family Physicians
Research
MEDLINE
Placenta
Observational Studies
Fertility
Case-Control Studies
Hemoglobins
Randomized Controlled Trials
Pharmacokinetics
Mothers
Morbidity

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Contemporary uses of erythropoietin in pregnancy : A literature review. / Sienas, Laura; Wong, Tienne; Collins, Rebecca; Smith, Jr., James.

In: Obstetrical and Gynecological Survey, Vol. 68, No. 8, 08.2013, p. 594-602.

Research output: Contribution to journalReview article

Sienas, Laura ; Wong, Tienne ; Collins, Rebecca ; Smith, Jr., James. / Contemporary uses of erythropoietin in pregnancy : A literature review. In: Obstetrical and Gynecological Survey. 2013 ; Vol. 68, No. 8. pp. 594-602.
@article{1afd6ba5d7634feca1c0e543f6bcd9eb,
title = "Contemporary uses of erythropoietin in pregnancy: A literature review",
abstract = "OBJECTIVE: The objectives of this study were to survey the current research and provide an update on the uses and benefits of erythropoietin (EPO) in pregnancy and the postpartum period. DATA SOURCES: A review of MEDLINE (1947 to present) was performed. Search terms included {"}erythropoietin,{"} {"}pregnan*,{"} with subheadings of {"}administration & dosage,{"} {"}pharmacokinetics,{"} {"}therapeutic use,{"} {"}fetus,{"} {"}fertility.{"} METHOD OF STUDY SELECTION: We reviewed relevant articles published from 2002 to 2012. Case reports, observational studies, case-control studies, randomized controlled trials, retrospective analyses, animal studies, and review articles were included. Articles were selected if they discussed a use of EPO in pregnancy or the immediate postpartum period, as well as use of EPO in the neonate. TABULATION, INTEGRATION, AND RESULTS: Authors independently reviewed and extracted data. Of the 65 articles reviewed, 45 were included. Erythropoietin was used in the treatment of maternal anemia. Because of the molecule's large size, recombinant EPO does not appear to cross the placenta. No fetal morbidity or mortality was noted. Therefore, this is a safe therapy that can be used in pregnancy. Use of EPO may be especially important for women who decline blood products. Neonatal uses of EPO show benefit in the treatment of anemia due to blood type incompatibility. CONCLUSIONS: Erythropoietin is gaining popularity as a therapeutic option during pregnancy and the postpartum period. Further investigation is needed to establish a standard dosage and dosing interval. New studies reviewing its use in the neonate for perinatal-hypoxic injury and anemia due to blood type incompatibility provide exciting opportunities for further therapeutic use. TARGET AUDIENCE: Obstetricians and gynecologists, family physicians LEARNING OBJECTIVES: After completing this CME activity, physicians should be better able to treat anemia in pregnancy, including causes and interventions; assess renal disease in pregnancy, targets of hemoglobin, precautions, and treatment considerations; and evaluate erythropoietin use in neonates and fetuses, including benefits, complications, and areas for upcoming research/uses.",
author = "Laura Sienas and Tienne Wong and Rebecca Collins and {Smith, Jr.}, James",
year = "2013",
month = "8",
doi = "10.1097/OGX.0b013e3182a2d51c",
language = "English",
volume = "68",
pages = "594--602",
journal = "Obstetrical and Gynecological Survey",
issn = "0029-7828",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Contemporary uses of erythropoietin in pregnancy

T2 - A literature review

AU - Sienas, Laura

AU - Wong, Tienne

AU - Collins, Rebecca

AU - Smith, Jr., James

PY - 2013/8

Y1 - 2013/8

N2 - OBJECTIVE: The objectives of this study were to survey the current research and provide an update on the uses and benefits of erythropoietin (EPO) in pregnancy and the postpartum period. DATA SOURCES: A review of MEDLINE (1947 to present) was performed. Search terms included "erythropoietin," "pregnan*," with subheadings of "administration & dosage," "pharmacokinetics," "therapeutic use," "fetus," "fertility." METHOD OF STUDY SELECTION: We reviewed relevant articles published from 2002 to 2012. Case reports, observational studies, case-control studies, randomized controlled trials, retrospective analyses, animal studies, and review articles were included. Articles were selected if they discussed a use of EPO in pregnancy or the immediate postpartum period, as well as use of EPO in the neonate. TABULATION, INTEGRATION, AND RESULTS: Authors independently reviewed and extracted data. Of the 65 articles reviewed, 45 were included. Erythropoietin was used in the treatment of maternal anemia. Because of the molecule's large size, recombinant EPO does not appear to cross the placenta. No fetal morbidity or mortality was noted. Therefore, this is a safe therapy that can be used in pregnancy. Use of EPO may be especially important for women who decline blood products. Neonatal uses of EPO show benefit in the treatment of anemia due to blood type incompatibility. CONCLUSIONS: Erythropoietin is gaining popularity as a therapeutic option during pregnancy and the postpartum period. Further investigation is needed to establish a standard dosage and dosing interval. New studies reviewing its use in the neonate for perinatal-hypoxic injury and anemia due to blood type incompatibility provide exciting opportunities for further therapeutic use. TARGET AUDIENCE: Obstetricians and gynecologists, family physicians LEARNING OBJECTIVES: After completing this CME activity, physicians should be better able to treat anemia in pregnancy, including causes and interventions; assess renal disease in pregnancy, targets of hemoglobin, precautions, and treatment considerations; and evaluate erythropoietin use in neonates and fetuses, including benefits, complications, and areas for upcoming research/uses.

AB - OBJECTIVE: The objectives of this study were to survey the current research and provide an update on the uses and benefits of erythropoietin (EPO) in pregnancy and the postpartum period. DATA SOURCES: A review of MEDLINE (1947 to present) was performed. Search terms included "erythropoietin," "pregnan*," with subheadings of "administration & dosage," "pharmacokinetics," "therapeutic use," "fetus," "fertility." METHOD OF STUDY SELECTION: We reviewed relevant articles published from 2002 to 2012. Case reports, observational studies, case-control studies, randomized controlled trials, retrospective analyses, animal studies, and review articles were included. Articles were selected if they discussed a use of EPO in pregnancy or the immediate postpartum period, as well as use of EPO in the neonate. TABULATION, INTEGRATION, AND RESULTS: Authors independently reviewed and extracted data. Of the 65 articles reviewed, 45 were included. Erythropoietin was used in the treatment of maternal anemia. Because of the molecule's large size, recombinant EPO does not appear to cross the placenta. No fetal morbidity or mortality was noted. Therefore, this is a safe therapy that can be used in pregnancy. Use of EPO may be especially important for women who decline blood products. Neonatal uses of EPO show benefit in the treatment of anemia due to blood type incompatibility. CONCLUSIONS: Erythropoietin is gaining popularity as a therapeutic option during pregnancy and the postpartum period. Further investigation is needed to establish a standard dosage and dosing interval. New studies reviewing its use in the neonate for perinatal-hypoxic injury and anemia due to blood type incompatibility provide exciting opportunities for further therapeutic use. TARGET AUDIENCE: Obstetricians and gynecologists, family physicians LEARNING OBJECTIVES: After completing this CME activity, physicians should be better able to treat anemia in pregnancy, including causes and interventions; assess renal disease in pregnancy, targets of hemoglobin, precautions, and treatment considerations; and evaluate erythropoietin use in neonates and fetuses, including benefits, complications, and areas for upcoming research/uses.

UR - http://www.scopus.com/inward/record.url?scp=84883421878&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883421878&partnerID=8YFLogxK

U2 - 10.1097/OGX.0b013e3182a2d51c

DO - 10.1097/OGX.0b013e3182a2d51c

M3 - Review article

VL - 68

SP - 594

EP - 602

JO - Obstetrical and Gynecological Survey

JF - Obstetrical and Gynecological Survey

SN - 0029-7828

IS - 8

ER -